Selected monoclonal antibodies in clinical trials in follicular non-Hodgkin lymphoma.
| Antibody name . | Type . | DLT . | OR rel FL, % . | Reference . |
|---|---|---|---|---|
| Abbreviations: DLT, ; OR rel FL | ||||
| Rituximab, anti-CD20 | Chimeric IgG1 | None | 48 | McLaughlin et al40 |
| Epratuzumab, anti-CD22 | Humanized IgG1 | None | 43 at 360 mg/m2 dose | Leonard et al17 |
| Epratuzumab + rituximab | Combination | None | 67 | Leonard et al19 |
| Inotuzumab ozogamicin | ||||
| Anti-CD22-calicheamicin | Humanized IgG4 | Decreased platelets | 69 | Fayad et al20 |
| Galiximab, anti-CD80 | Humanized IgG1 | None | 11 | Czuczman et al11 |
| Galiximab + rituximab | Combination | None | 66 | Leonard et al12 |
| SGN-40, anti-CD40 | Humanized IgG1 | Cytokine release | 0 | Advani et al13 |
| Antibody name . | Type . | DLT . | OR rel FL, % . | Reference . |
|---|---|---|---|---|
| Abbreviations: DLT, ; OR rel FL | ||||
| Rituximab, anti-CD20 | Chimeric IgG1 | None | 48 | McLaughlin et al40 |
| Epratuzumab, anti-CD22 | Humanized IgG1 | None | 43 at 360 mg/m2 dose | Leonard et al17 |
| Epratuzumab + rituximab | Combination | None | 67 | Leonard et al19 |
| Inotuzumab ozogamicin | ||||
| Anti-CD22-calicheamicin | Humanized IgG4 | Decreased platelets | 69 | Fayad et al20 |
| Galiximab, anti-CD80 | Humanized IgG1 | None | 11 | Czuczman et al11 |
| Galiximab + rituximab | Combination | None | 66 | Leonard et al12 |
| SGN-40, anti-CD40 | Humanized IgG1 | Cytokine release | 0 | Advani et al13 |